CTAG1B and acute myeloid leukemia: Similar results were reported in another phase I trial where seven patients with AML or MDS (a condition that precedes AML in many cases) were administered CDX-1401 (anti-DEC205 and NY-ESO-1), followed by several cycles of decitabine [91], Table 2.